Fortifeye Vitamins Unveils Groundbreaking Eye Pressure and Neuro Cognitive Support Supplement
Revolutionary Supplement for Optimal Eye Health and Cognitive Function EnhancementOCALA, FL / ACCESSWIRE / February 28, 2024 / Fortifeye, a...
Brain
FSD Pharma Announces Debt Settlement
TORONTO, ON / ACCESSWIRE / February 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW...
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey...
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to...
IRLAB to Present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7
GOTHENBURG, SWEDEN / ACCESSWIRE / February 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 28, 2024 - IRLAB Therapeutics...
Dynamaxx Revitalizes Its Product Portfolio, Launches Nine Enhanced and Newly Formulated Offerings: Full Alliance Group (OTC: “FAGI”)
TAMPA, FL / ACCESSWIRE / February 27, 2024 / Full Alliance Group, Inc. (OTC PINK:FAGI) wholly owned subsidiary DYNAMAXX, is...
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a...
AlzeCure Publishes its Year-end Report for January – December 2023
STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced...
IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases
GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics...
Zeto Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance
HITRUST Risk-Based, 2-year (r2) Certification validates Zeto is committed to strong cybersecurity and protecting sensitive dataSANTA CLARA, CA / ACCESSWIRE...
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / February 26, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Bedtime drug being developed by Tonix relieved pain by targeting fibromyalgia's characteristic "non-restorative sleep": Potential for FDA Approval in 2025CHATHAM,...
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and...
Notice of Nexstim Plc’s 2023 Full Year Results
Press release, Helsinki, 22 February 2024 at 3 PM (EET) Notice of Nexstim Plc’s 2023 Full Year Results Nexstim Plc...
BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System
LAS VEGAS, NV, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and...
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause...
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific...